Full Press Release Details
ADC Therapeutics to Participate in the 41st
Annual J.P. Morgan Healthcare Conference
LAUSANNE, Switzerland,
January 4, 2023 - ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present
a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th
the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website,
ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation,
targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment
paradigm for patients with hematologic malignancies and solid tumors.
CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large
B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition
to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit https://adctherapeutics.com/ and follow the Company on Twitter
ZYNLONTA is a registered
trademark of ADC Therapeutics SA.
Forward-Looking Statements
press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability
to continue to commercialize ZYNLONTA in the United States and future
revenue from the same; Swedish Orphan Biovitrum AB (Sobi ) ability to
successfully commercialize ZYNLONTA in the European Economic Area and
market acceptance, adequate reimbursement coverage, and future revenue from the same; our strategic partners', including Mitsubishi
Tanabe Pharma Corporation and Overland Pharmaceuticals, ability to obtain regulatory approval for ZYNLONTA
in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the
Company's ability to market its products in compliance with applicable laws and regulations; the timing and results of the Company's
or its partners' research projects or clinical trials including LOTIS 2, 5 and 9, ADCT 901, 601 and 212, the timing and outcome
of regulatory submissions and actions by the FDA or other regulatory agencies with respect to the Company's products or product
candidates; projected revenue and expenses, the Company's indebtedness including Healthcare Royalty Management and Oak Tree
facilities and the restrictions imposed on the Company's activities by such indebtedness, the
to repay such indebtedness and the significant cash required to service such indebtedness; the Company's ability to obtain financial
and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are
not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that
may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by
terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'',
''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors
that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk
Factors" section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained
in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by law.